Trial Profile

A phase IIb/III trial of JKB-122 in Post-acute-COVID-19-syndrome

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JKB 122 (Primary)
Indications Post acute COVID 19 syndrome
Focus Therapeutic Use

Most Recent Events

28 Apr 2026 New trial record
25 Mar 2026 According to DifGen Pharmaceuticals media release, company announced that the FDA has completed the review of IND and concluded that it is reasonably safe to proceed with Phase 2b/3 study, as amended. FDA will issue the Study May Proceed letter with non-hold comments by April 20th

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com